#startup · 8sync News

Alan raises €480M led by Prosus at €5.5bn

French health insurtech Alan has raised €480M in a Series G round led by Prosus at a €5.5bn valuation, just three months after a previous €100M raise. The company, which now has over €1.2bn in total funding, is profitable in France, serves 1.1 million members, and posted €800M+ in ARR growing 53% year-on-year. Alan's pitch centers on 'prevention insurance' — bundling health cover, care navigation, and AI-driven health assistance into a single app to shift healthcare from reactive to proactive. The capital will fund expansion into new markets, deeper AI investment, and potential acquisitions. The deal is one of Europe's largest non-AI raises of 2025 and a rare bright spot for French tech amid declining startup funding.

The Bullseye Model of product velocity

The Bullseye Model reframes software delivery success beyond raw deployment speed. Using an archery metaphor, it argues that teams need both throughput and directional accuracy — consistently moving toward an ideal product-market fit. Speed matters only insofar as it enables faster feedback loops and course correction; excess velocity without feedback is wasteful or harmful. The model also addresses AI-assisted development, warning that increased throughput requires mature deployment pipelines and governance, or gains will be lost to bottlenecks. The real metric is how quickly a team closes the gap between their current product and the ideal one.

Tombot raises $7m to bring its robotic dog Jennie to market

Tombot has closed a $7 million Series A3 round to scale manufacturing of Jennie, its autonomous robotic Labrador puppy designed as a companion for people with dementia, cognitive impairment, anxiety, loneliness, autism, and PTSD. Investors include healthcare and aging-services backers such as Caduceus Capital Partners and the Lutheran Foundation for Long Term Living. The company reports over 23,000 pre-orders and waitlist sign-ups ahead of a planned Fall 2026 commercial launch — its first shipments to paying customers. Jennie mimics the behavior of an 8-to-10-week-old puppy and is pitched as delivering companionship benefits without the care burden of a live animal.

Tissium raises €60M for sutureless nerve repair

Paris-based medtech Tissium has raised €60M (a €30M Series D2 round plus a €30M EIB credit line) to commercialize COAPTIUM CONNECT, the only FDA-cleared sutureless nerve repair system. Instead of stitching severed nerves with needles, the device uses a 3D-printed chamber and a light-cured synthetic polymer to seal nerve ends without penetrating tissue. A 12-patient study showed 100% recovery of full movement with no pain at one year. The product launched in the US in November 2025. Tissium competes in a peripheral nerve repair market worth $13.4bn in 2025, projected to reach $30.5bn by 2033, against incumbents like Axogen and Integra LifeSciences that still rely on donor tissue and sutures. The funding will support US commercial expansion and pipeline products including a hernia repair device.

Stark Defence raises €500M led by Sequoia and Founders Fund at a valuation above €3.5 billion

Berlin-based drone startup Stark Defence has raised €500M in a round led by Sequoia Capital and Founders Fund, pushing its valuation past €3.5 billion just two years after founding. The company builds loitering munitions (kamikaze drones), with its flagship Virtus drone already deployed in Ukraine. Over 80% of the new capital will go toward manufacturing and R&D expansion. The raise comes amid a broader European defence tech funding surge, with rivals Helsing and Quantum Systems also raising large rounds. Germany awarded Stark and Helsing initial contracts worth ~€269M each for drones to equip the Bundeswehr. Global defence tech VC reached $49B in 2025, nearly double the prior year, driven by EU rearmament plans and the war in Ukraine.

Astral Systems £23M raise targets cancer isotopes

Bristol-based Astral Systems has closed the first tranche of a £23M Series A led by Mercia Ventures, bringing total funding past £28M. Unlike most fusion companies chasing clean energy, Astral uses its multi-state fusion reactors to produce radioactive isotopes for cancer diagnostics and treatment — a market with a fragile, aging global supply chain and almost no UK production. The company already operates three commercial fusion facilities and holds £3M+ in research contracts. New capital will fund a site at the decommissioned Berkeley Power Station in Gloucestershire, where Astral plans to run next-generation reactors by end of 2026, target profitability in 2027, and bring isotopes Actinium-225 and Lead-212 to market by early 2027. The global nuclear medicine market is projected to grow from $17.77B in 2024 to $34.51B by 2030.

Fika Jobs raises $4M to build a video-first hiring platform where AI agents interview candidates

Stockholm-based Fika Jobs has raised $4M in pre-seed funding to build a video-first hiring platform that uses AI agents (powered by Google Gemini) to conduct candidate interviews. Instead of traditional resumes, candidates complete a ~10-minute AI video interview, which is then turned into short video clips forming a live profile that employers can browse. Unlike competitors focused on employer-side screening, Fika centers the experience on candidates maintaining persistent video profiles. The platform is free for job seekers; employers pay a 10% placement fee on first-year salary upon a successful hire. Early access opens this week, with a broader launch planned for fall 2026, starting in Sweden. The round was led by Luminar Ventures.